Compare Amylx Pharmaceuticals Inc (AMLX) vs Dropbox Inc (DBX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Dropbox Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Dropbox Inc trades at $29.17 (market cap $6.81B). The key difference: Dropbox Inc is far larger — about 3.4× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Dropbox Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | DBX | |
|---|---|---|
Market Cap | $1.98B | $6.81B |
Sector | Health | Technology |
52-Week High | $18.70 | $32.17 |
52-Week Low | $7.64 | $22.06 |
Enterprise Value | $1.70B | $9.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
DBX trades at $29.19, down 0.75% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported revenue of $2.52 billion in 2025 with a net income margin of 20.16%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights a $900 million stock repurchase program and CEO transition plans announced in May 2026.
Outlook is mixed with strong profitability and consistent earnings beats offset by negative shareholder equity and high debt levels. The consensus price target of $30 suggests modest upside, but investors face risks from leadership changes and competitive pressures in cloud storage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →
